drug · small molecule

amantadine hydrochloride

Phase 2updated 3mo ago

by Shinkei Therapeutics LLC🔗 ChEMBL

Phase 2

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

targets

Matrix protein 2Glutamate [NMDA] receptor

all catalysts(0)

nothing on the calendar yet

Trials studying amantadine hydrochloride

phase2Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).active not recruitingn=45
phase2Urinary Excretion of Acetylamantadine by Cancer Patientscompletedn=150

News(1)

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
biospace · 11d ago

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 10m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

amantadine hydrochloride

Phase 2updated 3mo ago

by Shinkei Therapeutics LLC🔗 ChEMBL

Phase 2

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

targets

Matrix protein 2Glutamate [NMDA] receptor

all catalysts(0)

nothing on the calendar yet

Trials studying amantadine hydrochloride

phase2Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).active not recruitingn=45
phase2Urinary Excretion of Acetylamantadine by Cancer Patientscompletedn=150

News(1)

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
biospace · 11d ago

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 10m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

amantadine hydrochloride

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying amantadine hydrochloride

News(1)

Report a data issue

comments(0)

amantadine hydrochloride

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying amantadine hydrochloride

News(1)

Report a data issue

comments(0)